| 1. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 2. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 3. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 4. |
- Aad, G., et al.
(författare)
-
- 2012
-
swepub:Mat__t (refereegranskat)
|
|
| 5. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 6. |
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 7. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 8. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 9. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 10. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 11. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 12. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 13. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 14. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 15. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 16. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 17. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 18. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 19. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 20. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 21. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t (refereegranskat)
|
|
| 22. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 23. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 24. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 25. |
- Aad, G., et al.
(författare)
-
- 2012
-
Tidskriftsartikel (refereegranskat)
|
|
| 26. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 27. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 28. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 29. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 30. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 31. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 32. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 33. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t (refereegranskat)
|
|
| 34. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t
|
|
| 35. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t
|
|
| 36. |
- Aad, G., et al.
(författare)
-
- 2011
-
swepub:Mat__t
|
|
| 37. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t
|
|
| 38. |
- Aad, G., et al.
(författare)
-
- 2010
-
swepub:Mat__t
|
|
| 39. |
|
|
| 40. |
|
|
| 41. |
|
|
| 42. |
- Fabian, ID, et al.
(författare)
-
Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries
- 2021
-
Ingår i: The British journal of ophthalmology. - : BMJ. - 1468-2079 .- 0007-1161. ; 105:10, s. 1435-1443
-
Tidskriftsartikel (refereegranskat)abstract
- The travel distance from home to a treatment centre, which may impact the stage at diagnosis, has not been investigated for retinoblastoma, the most common childhood eye cancer. We aimed to investigate the travel burden and its impact on clinical presentation in a large sample of patients with retinoblastoma from Africa and Europe.MethodsA cross-sectional analysis including 518 treatment-naïve patients with retinoblastoma residing in 40 European countries and 1024 treatment-naïve patients with retinoblastoma residing in 43 African countries.ResultsCapture rate was 42.2% of expected patients from Africa and 108.8% from Europe. African patients were older (95% CI −12.4 to −5.4, p<0.001), had fewer cases of familial retinoblastoma (95% CI 2.0 to 5.3, p<0.001) and presented with more advanced disease (95% CI 6.0 to 9.8, p<0.001); 43.4% and 15.4% of Africans had extraocular retinoblastoma and distant metastasis at the time of diagnosis, respectively, compared to 2.9% and 1.0% of the Europeans. To reach a retinoblastoma centre, European patients travelled 421.8 km compared to Africans who travelled 185.7 km (p<0.001). On regression analysis, lower-national income level, African residence and older age (p<0.001), but not travel distance (p=0.19), were risk factors for advanced disease.ConclusionsFewer than half the expected number of patients with retinoblastoma presented to African referral centres in 2017, suggesting poor awareness or other barriers to access. Despite the relatively shorter distance travelled by African patients, they presented with later-stage disease. Health education about retinoblastoma is needed for carers and health workers in Africa in order to increase capture rate and promote early referral.
|
|
| 43. |
- Schiava, M., et al.
(författare)
-
Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study
- 2022
-
Ingår i: Journal of Neurology Neurosurgery and Psychiatry. - : BMJ. - 0022-3050 .- 1468-330X. ; 93:10, s. 1099-1111
-
Tidskriftsartikel (refereegranskat)abstract
- Background Valosin-containing protein (VCP) disease, caused by mutations in the VCP gene, results in myopathy, Paget's disease of bone (PBD) and frontotemporal dementia (FTD). Natural history and genotype-phenotype correlation data are limited. This study characterises patients with mutations in VCP gene and investigates genotype-phenotype correlations. Methods Descriptive retrospective international study collecting clinical and genetic data of patients with mutations in the VCP gene. Results Two hundred and fifty-five patients (70.0% males) were included in the study. Mean age was 56.8 +/- 9.6 years and mean age of onset 45.6 +/- 9.3 years. Mean diagnostic delay was 7.7 +/- 6 years. Symmetric lower limb weakness was reported in 50% at onset progressing to generalised muscle weakness. Other common symptoms were ventilatory insufficiency 40.3%, PDB 28.2%, dysautonomia 21.4% and FTD 14.3%. Fifty-seven genetic variants were identified, 18 of these no previously reported. c.464G>A (p.Arg155His) was the most frequent variant, identified in the 28%. Full time wheelchair users accounted for 19.1% with a median time from disease onset to been wheelchair user of 8.5 years. Variant c.463C>T (p.Arg155Cys) showed an earlier onset (37.8 +/- 7.6 year) and a higher frequency of axial and upper limb weakness, scapular winging and cognitive impairment. Forced vital capacity (FVC) below 50% was as risk factor for being full-time wheelchair user, while FVC Conclusion This study expands the knowledge on the phenotypic presentation, natural history, genotype-phenotype correlations and risk factors for disease progression of VCP disease and is useful to improve the care provided to patient with this complex disease.
|
|
| 44. |
- Lacson, John Charles A., et al.
(författare)
-
Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families
- 2021
-
Ingår i: BMC Public Health. - : Springer Science and Business Media LLC. - 1471-2458. ; 21:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Individuals from melanoma-prone families have similar or reduced sun-protective behaviors compared to the general population. Studies on trends in sun-related behaviors have been temporally and geographically limited. Methods: Individuals from an international consortium of melanoma-prone families (GenoMEL) were retrospectively asked about sunscreen use, sun exposure (time spent outside), sunburns, and sunbed use at several timepoints over their lifetime. Generalized linear mixed models were used to examine the association between these outcomes and birth cohort defined by decade spans, after adjusting for covariates. Results: A total of 2407 participants from 547 families across 17 centers were analyzed. Sunscreen use increased across subsequent birth cohorts, and although the likelihood of sunburns increased until the 1950s birth cohort, it decreased thereafter. Average sun exposure did not change across the birth cohorts, and the likelihood of sunbed use increased in more recent birth cohorts. We generally did not find any differences in sun-related behavior when comparing melanoma cases to non-cases. Melanoma cases had increased sunscreen use, decreased sun exposure, and decreased odds of sunburn and sunbed use after melanoma diagnosis compared to before diagnosis. Conclusions: Although sunscreen use has increased and the likelihood of sunburns has decreased in more recent birth cohorts, individuals in melanoma-prone families have not reduced their overall sun exposure and had an increased likelihood of sunbed use in more recent birth cohorts. These observations demonstrate partial improvements in melanoma prevention and suggest that additional intervention strategies may be needed to achieve optimal sun-protective behavior in melanoma-prone families.
|
|
| 45. |
- Taylor, Nicholas J., et al.
(författare)
-
Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families
- 2017
-
Ingår i: Journal of Investigative Dermatology. - : Elsevier BV. - 0022-202X .- 1523-1747. ; 137:12, s. 2606-2612
-
Tidskriftsartikel (refereegranskat)abstract
- Germline mutations in CDKN2A are frequently identified among melanoma kindreds and are associated with increased atypical nevus counts. However, a clear relationship between pathogenic CDKN2A mutation carriage and other nevus phenotypes including counts of common acquired nevi has not yet been established. Using data from GenoMEL, we investigated the relationships between CDKN2A mutation carriage and 2-mm, 5-mm, and atypical nevus counts among blood-related members of melanoma families. Compared with individuals without a pathogenic mutation, those who carried one had an overall higher prevalence of atypical (odds ratio = 1.64; 95% confidence interval = 1.18–2.28) nevi but not 2-mm nevi (odds ratio = 1.06; 95% confidence interval = 0.92–1.21) or 5-mm nevi (odds ratio = 1.26; 95% confidence interval = 0.94–1.70). Stratification by case status showed more pronounced positive associations among non-case family members, who were nearly three times (odds ratio = 2.91; 95% confidence interval = 1.75–4.82) as likely to exhibit nevus counts at or above the median in all three nevus categories simultaneously when harboring a pathogenic mutation (vs. not harboring one). Our results support the hypothesis that unidentified nevogenic genes are co-inherited with CDKN2A and may influence carcinogenesis.
|
|
| 46. |
- Taylor, Nicholas J, et al.
(författare)
-
Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT
- 2019
-
Ingår i: Journal of the American Academy of Dermatology. - : Elsevier BV. - 0190-9622 .- 1097-6787. ; 81:2, s. 386-394
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Although rare in the general population, highly penetrant germline mutations in CDKN2A are responsible for 5-40% of melanoma cases reported in melanoma-prone families. We sought to determine whether MELPREDICT was generalizable to a global series of melanoma families and whether performance improvements can be achieved.METHODS: 2,116 familial melanoma cases were ascertained by the international GenoMEL Consortium. We recapitulated the MELPREDICT model within our data (GenoMELPREDICT) to assess performance improvements by adding phenotypic risk factors and history of pancreatic cancer. We report areas under the curve (AUC) with 95% confidence intervals (CI) along with net reclassification indices (NRI) as performance metrics.RESULTS: MELPREDICT performed well (AUC=0.752; 95%CI: 0.730, 0.775), and GenoMELPREDICT performance was similar (AUC=0.748; 95% CI: 0.726, 0.771). Adding a reported history of pancreatic cancer yielded discriminatory improvement (p<0.0001) in GenoMELPREDICT (AUC=0.772; 95%CI: 0.750, 0.793; NRI=0.40). Including phenotypic risk factors did not improve performance.CONCLUSION: The MELPREDICT model functioned well in a global dataset of familial melanoma cases. Adding pancreatic cancer history improved model prediction. GenoMELPREDICT is a simple tool for predicting CDKN2A mutational status among melanoma patients from melanoma-prone families and can aid in counselling these patients towards genetic testing or cancer risk counselling.
|
|
| 47. |
|
|
| 48. |
|
|
| 49. |
|
|
| 50. |
|
|
